Medibact GuidesShop at Medibact

Stacking Module

PE-22-28 Stacking Module

PE-22-28 is a spadin-derived TREK-1 channel inhibitor with an unusually specific proposed mechanism for this catalog — a named ion channel rather than a broad signalling pathway. Its stacking discussion is correspondingly thin, which is honest given how little human data exist.

PE-22-28 Guide at MedibactPE-22-28 calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking PE-22-28

  • PE-22-28 is reported to inhibit the TREK-1 potassium channel, a mechanism implicated in antidepressant research. That is genuinely distinct from the monoamine and BDNF framings of the other neuro peptides.
  • Human data are essentially absent; the evidence is preclinical.
  • Because its mechanism does not overlap the other neuro compounds, redundancy is not the main concern here — the absence of any human safety data is.
  • No controlled trial has studied it combined with anything.

Combinations in detail

Cognitive/mood stack

PE-22-28 + Semax or Selank
Why it is proposed
Distinct mechanisms in the same domain: TREK-1 inhibition alongside BDNF-oriented or monoamine-oriented modulation. Non-overlapping on mechanism.
What is reported in practice
Reported in nootropic discussion; PE-22-28 is reported both intranasally and by injection.
Cautions specific to this combination
PE-22-28 has the thinnest human evidence of anything in the neuro group, and combining an uncharacterised compound with contested ones does not improve either. Mood symptoms warrant clinical assessment rather than a research-peptide stack.

What to avoid, and why

  • Treating preclinical antidepressant research as applicable to self-directed use for mood symptoms.
  • Combining it with prescribed psychiatric medication without clinical input — the interaction profile is entirely uncharacterised.
  • Reading its mechanistic specificity as evidence of efficacy; a named target is not a demonstrated effect.

Related reading

The Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.